Populations with a high prevalence of AIDS-immunocompromised people are more likely to see the emergence of antibiotic-resistant bacterial infections, according to a study coauthored by researchers at the University of Tennessee, Knoxville, and published in PLOS One.
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS. This combination is deadly: it makes patient diagnosis and treatment difficult, and increases the pathogenicity of these two infectious agents. A team led by researchers at the CNRS and Inserm have revealed that in the presence of tuberculosis, HIV-1 moves from one cell to the next via nanotubes which form between macrophages, drastically increasing the percentage of infected cells.
Privacy concerns linked to both health facilities and providers are major barriers to increasing the number of men who are tested and treated for HIV in Cote d'Ivoire, suggests new Johns Hopkins Center for Communication Programs (CCP) research. CCP is based at the Johns Hopkins Bloomberg School of Public Health.
While current therapies for HIV can successfully manage active infection, the virus can survive in tissue reservoirs, including macrophage cells, and remain a persistent problem. Now, Dr. David Russell, William Kaplan Professor of Infection Biology at Cornell University College of Veterinary Medicine, and his research team have pinpointed a novel angle of attack that could selectively eradicate these viral reservoir cells while leaving healthy cells untouched.
Teens and young adults who were exposed to HIV and antiretroviral therapy before birth but are HIV-negative themselves are at increased risk of obesity and asthma-like symptoms, according to research to be presented Saturday, March 23 at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
A new study, published this month in Lancet HIV by Penn Medicine researchers, shows that a naltrexone implant placed under the skin was more effective at helping HIV-positive patients with an opioid addiction reduce relapse and have better HIV-related outcomes compared to the oral drug.
Experiments with mice suggest that treatment with atorvastatin can attenuate adipose tissue remodeling, leading to rapid weight loss and muscle atrophy.
An international team of researchers presents a comprehensive and renewed focus on the common, yet poorly understood condition of bacterial vaginosis (BV) and how the microbial make-up of the vagina can affect a woman's risk of acquiring HIV and AIDS.
Lucie Cluver, Professor of Child and Family Social Work in Oxford's Department of Social Policy and Intervention, is the principal investigator and lead author with Mark Orkin, Visiting Professor in the Developmental Pathways to Health Research Unit (DPHRU) in the Department of Paediatrics & Child Health, School of Clinical Medicine at Wits University.
Academics led by Professor Lucie Cluver at Oxford University have shown how key services in lower and middle-income countries can contribute to multiple sustainable development goals (SDGs), even for the highest-risk children and adolescents.